Avastin in neovascular glaucoma

Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma

Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma from the February 2009 issue of the British Journal of Ophthalmology.

Please click here to read the full story.

Related Videos
Related Content

Preparing for surgical success

March 17th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Choosing the right IOL for the right patient: visual performance and stability of a modified aspheric monofocal IOL

March 17th 2023

Updates From Angiogenesis-2022

February 11th 2022

The advantages of a digital workflow in modern cataract surgery

March 17th 2023

Paying attention to ocular surface disease preoperatively matters

March 16th 2023

Preparing for surgical success

March 17th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Choosing the right IOL for the right patient: visual performance and stability of a modified aspheric monofocal IOL

March 17th 2023

Updates From Angiogenesis-2022

February 11th 2022

The advantages of a digital workflow in modern cataract surgery

March 17th 2023

Paying attention to ocular surface disease preoperatively matters

March 16th 2023

Preparing for surgical success

March 17th 2023

Long-Term Efficacy and Durability of Latest Therapies in neovascular AMD and DMO

December 19th 2022

Choosing the right IOL for the right patient: visual performance and stability of a modified aspheric monofocal IOL

March 17th 2023

Updates From Angiogenesis-2022

February 11th 2022

The advantages of a digital workflow in modern cataract surgery

March 17th 2023

Paying attention to ocular surface disease preoperatively matters

March 16th 2023
© 2023 MJH Life Sciences

All rights reserved.